Propranolol Accelerats Hemangioma Stem Cell Transformation Into Adipocyte

Area of Science:

• Vascular Biology
• Developmental Biology
• Pharmacology

Background:

• Infantile hemangioma (IH) is the most common childhood benign vascular tumor.
• Propranolol is an effective therapy for IH, but its mechanism of action is unclear.
• Hemangioma stem cells (HemSCs) possess mesenchymal characteristics and multilineage differentiation potential.

Purpose of the Study:

• To investigate the effect of propranolol on hemangioma stem cells (HemSCs).
• To determine if propranolol accelerates HemSC transdifferentiation and inhibits IH growth.

Main Methods:

• Isolated HemSCs using CD133-tagged immunomagnetic beads.
• Analyzed HemSC phenotypes and propranolol-induced cell death via flow cytometry.
• Assessed proliferation and adipogenesis using MTT assay, Oil red O staining, and Western blotting.

Main Results:

• HemSCs exhibited mesenchymal morphology and expressed CD90 and CD105.
• Propranolol inhibited HemSC proliferation and induced cell death/apoptosis in a concentration-dependent manner at high concentrations (≥100 μM).
• Propranolol treatment significantly increased HemSC adipogenic differentiation, evidenced by Oil red O staining and increased expression of phosphorylated AKT and PPARγ.

Conclusions:

• Propranolol inhibits HemSC proliferation, induces apoptosis, and promotes differentiation.
• Propranolol may upregulate PPARγ via PI3K pathways, enhancing IH HemSC adipogenesis and contributing to therapeutic efficacy.